Fig. 8

LCN2 acts on the downstream MAPK signaling pathway by binding to Fn14, and the deletion of Fn14 can counteract the effect of TWEAK or LCN2. A KRT6, KRT16, LCN2 were detected by WB in the skin of wild-type mice as well as in the Fn14^–/– mouse imiquimod model. (n = 3 per group). B Immunohistochemistry was used to detect the expression of KRT5 and KRT14 in the skin of wild-type mice and Fn14^–/– mice (Brown). Nuclei were stained with hematoxylin (Bar = 200 μm). C WB detected p-ERK1/2, p-JNK and p-p38 expression in wild-type mice and Fn14^–/– mouse. (n = 3 per group). D Tnfsf12, Tnfrsf12a, Lcn2, Il1b, Il6, Krt5, Krt16, and Krt17 mRNA expression levels were detected by using RT-qPCR methods. E Immunohistochemistry was used to detect the levels of LCN2 and Ly6G in the epidermis of Fn14^–/– mouse imiquimod model after administration of TWEAK. F After treated by LCN2 or TWEAK, Western blot was used to detect the expression of KRT5, KRT6, KRT14, and KRT16 in the Fn14^–/– mice skin tissue. (n = 3 per group) Data were pooled from three independent experiments. Data are shown as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001. SPR surface plasmon resonance